We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

109 hedge funds and large institutions have $1.02B invested in Aclaris Therapeutics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 43 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

432% more call options, than puts

Call options by funds: $1.15M | Put options by funds: $217K

25% more capital invested

Capital invested by funds: $815M → $1.02B (+$203M)

13% more funds holding in top 10

Funds holding in top 10: 8 → 9 (+1)

5.23% more ownership

Funds ownership: 91.53% → 96.76% (+5.2%)

14% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 43

18% less funds holding

Funds holding: 133 → 109 (-24)

68% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 31

Holders
109
Holders Change
-24
Holders Change %
-18.05%
% of All Funds
1.72%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.14%
New
10
Increased
37
Reduced
43
Closed
31
Calls
$1.15M
Puts
$217K
Net Calls
+$937K
Net Calls Change
-$1.18M

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$31.1M
2
RCM
RA Capital Management
Massachusetts
+$24.8M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$22.3M
4
Deutsche Bank
Deutsche Bank
Germany
+$16.5M
5
O
OrbiMed
New York
+$8.1M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$13.1M
2
FCMI
Foresite Capital Management IV
California
-$6.82M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.48M
4
FM
Frazier Management
Washington
-$5.94M
5
PA
Perceptive Advisors
New York
-$5.43M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northwestern Mutual Wealth Management
101
Northwestern Mutual Wealth Management
Wisconsin
$9K – – –
HNWAG
102
High Net Worth Advisory Group
Florida
$9K +$6.82K +500 New
SCM
103
Silverarc Capital Management
Massachusetts
$4.75K -$149K -10,893 -4%
LC
104
Lindbrook Capital
California
$4K +$2.84K +208 New
Daiwa Securities Group
105
Daiwa Securities Group
Japan
$3K – – –
S
106
SignatureFD
Georgia
$1K -$273 -20 -32%
MPWT
107
MassMutual Private Wealth & Trust
Connecticut
$1K +$750 +55 New
QCG
108
Quadrant Capital Group
Ohio
$1K +$1.15K +84 New
Macquarie Group
109
Macquarie Group
Australia
$27 – – –
CAM
110
Cormorant Asset Management
Massachusetts
– -$13.1M -900,000 Closed
FM
111
Frazier Management
Washington
– -$5.94M -408,329 Closed
DGM
112
Darwin Global Management
Jersey
– -$3.14M -216,143 Closed
HLA
113
Hamilton Lane Advisors
Pennsylvania
– -$1.42M -97,550 Closed
TLP
114
Tri Locum Partners
New York
– -$806K -55,433 Closed
PVI
115
Pura Vida Investments
New York
– -$702K -48,266 Closed
Franklin Resources
116
Franklin Resources
California
– -$611K -41,994 Closed
JF
117
Jump Financial
Illinois
– -$465K -32,000 Closed
Jane Street
118
Jane Street
New York
– -$426K -31,228 Closed
SCP
119
Sender Company & Partners
New York
– -$438K -30,132 Closed
EGM
120
Engineers Gate Manager
New York
– -$399K -27,453 Closed
MAM
121
Martingale Asset Management
Massachusetts
– -$345K -23,702 Closed
D.E. Shaw & Co
122
D.E. Shaw & Co
New York
– -$332K -22,864 Closed
Victory Capital Management
123
Victory Capital Management
Texas
– -$329K -22,650 Closed
AGM
124
Alpine Global Management
New York
– -$298K -20,528 Closed
FRM
125
Fox Run Management
Connecticut
– -$282K -19,368 Closed
2 3 4
5
6

ACRS Hedge Fund Activity: Q1 2022 in Review

109 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2022, worth a combined $1.02B — up 25% from $815M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of ACRS and 10 opened new positions — a net loss of 21 holders — while 43 trimmed existing stakes and 37 added.

The largest buyer was BVF Inc, adding an estimated $31.1M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $13.1M sold.

  • 109 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2022, down from 133 in Q4 2021.
  • Funds reported $1.02B of Aclaris Therapeutics stock for Q1 2022, up 25% quarter-over-quarter.
  • 10 funds opened new Aclaris Therapeutics positions in Q1 2022 and 31 closed out, a net change of -21 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2022 was BVF Inc, an estimated $31.1M added.
  • The largest Aclaris Therapeutics seller in Q1 2022 was Cormorant Asset Management, an estimated $13.1M sold.

Based on aggregated 13F filings for Q1 2022.